<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> is the most common form of <z:hpo ids='HP_0000726'>dementia</z:hpo>, affecting more than one-third of Americans older than 85 years </plain></SENT>
<SENT sid="1" pm="."><plain>It is characterized by progressive <z:hpo ids='HP_0002354'>memory loss</z:hpo> and <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Amyloid plaque accumulation, neurofibrillary tau tangles, and <z:mpath ids='MPATH_63'>depletion</z:mpath> of <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> are among the pathologic manifestations of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although there are no proven modalities for preventing <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> treatment, <z:chebi fb="0" ids="25681">omega-3 fatty acid</z:chebi> supplementation, physical activity, and cognitive engagement demonstrate modest potential </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="38462">Acetylcholinesterase inhibitors</z:chebi> are first-line medications for the treatment of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>, and are associated with mild improvements in cognitive function, behavior, and activities of daily living; however, the clinical relevance of these effects is unclear </plain></SENT>
<SENT sid="5" pm="."><plain>The most common adverse effects of <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitors</z:chebi> are <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, dizziness, <z:hpo ids='HP_0001289'>confusion</z:hpo>, and <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Short-term use of the <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> memantine can modestly improve measures of cognition, behavior, and activities of daily living in patients with moderate to severe <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Memantine can also be used in combination with <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitors</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Memantine is generally well tolerated, but whether its benefits produce clinically meaningful improvement is controversial </plain></SENT>
<SENT sid="9" pm="."><plain>Although <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> and <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitors</z:chebi> can slow the progression of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>, no pharmacologic agents can reverse the progression </plain></SENT>
<SENT sid="10" pm="."><plain>Atypical <z:chebi fb="0" ids="35476">antipsychotics</z:chebi> can improve some behavioral symptoms, but have been associated with increased mortality rates in older patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>There is conflicting evidence about the benefit of <z:chebi fb="0" ids="9086">selegiline</z:chebi>, <z:chebi fb="51" ids="17347">testosterone</z:chebi>, and ginkgo for the treatment of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>There is no evidence supporting the beneficial effects of vitamin E, <z:chebi fb="0" ids="50114">estrogen</z:chebi>, or <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drug</z:chebi> therapy </plain></SENT>
</text></document>